Novartis

FDA approves first drug formulated for children with rare brain tumor

Monday, September 3, 2012 08:25 AM

The FDA has approved Novartis’ Afinitor Disperz (everolimus tablets for oral suspension), a new pediatric dosage form of the anti-cancer drug Afinitor used to treat subependymal giant cell astrocytoma (SEGA, a rare brain tumor).

More... »

Sosei, Novartis tout positive results for phase III QVA149 study in COPD

Thursday, August 30, 2012 03:19 PM

Novartis and Sosei Group, an international biopharmaceutical company based in Japan, released results from the fifth QVA149 (indacaterol maleate / glycopyrronium bromide) phase III study, SPARK, which met its primary endpoint of a reduced rate of moderate-to-severe COPD exacerbations compared to glycopyrronium bromide (Seebri Breezhaler).

More... »

Breast cancer drug market will be driven by 3 agents, says Decision Resources

Monday, August 20, 2012 02:18 PM

Three new breast cancer market entrants—Roche/Genentech’s Perjeta (pertuzumab) and trastuzumab-DM1 (T-DM1), and Novartis’s Afinitor (everolimus)—will drive growth in the breast cancer market through 2021, according to Decision Resources, a research and advisory firm for pharmaceutical and healthcare issues.

More... »

ThromboGenics publishes phase III data of ocriplasmin for VMT

Friday, August 17, 2012 03:11 PM

ThromboGenics, a Belgium-based biopharmaceutical company focused on ophthalmic medicines, has published data from two phase III clinical trials evaluating ocriplasmin for the treatment of Vitreomacular Adhesion (VMA) and macular holes in the New England Journal of Medicine.

More... »

Novartis, University of Penn. to expand use of personalized T cell therapy

Monday, August 6, 2012 12:44 PM

Aimed at bringing a new, personalized immunotherapy approach to patients with a wide variety of cancers, the University of Pennsylvania and Switzerland-based Novartis inked an exclusive global research and licensing agreement to further study and commercialize novel cellular immunotherapies using chimeric antigen receptor (CAR) technologies.

More... »

Endocyte appoints Novartis vet David Meek as chief commercial officer

Monday, July 30, 2012 03:49 PM

Endocyte, an Indianapolis, Ind.-based biopharmaceutical company focused on cancer and inflammatory diseases, has appointed David Meek to the newly created position of chief commercial officer. He will be responsible for the development of Endocyte’s commercial team and overall commercial strategy and execution.

More... »

Genentech and Novartis rank as image leaders among oncologists, hematologists

Wednesday, July 25, 2012 09:59 AM

Genentech and Novartis have the best image among oncologists and hematologists, according to Market Strategies International, a market research consultancy that recently completed its 2012 Oncology Image Study.

More... »

Novartis’ Gilenya earns positive results in extended phase III head-to-head study

Monday, June 11, 2012 02:52 PM

New long-term data for Gilenya (fingolimod), the only oral therapy approved to treat people with relapsing forms of multiple sclerosis (MS), show a sustained efficacy benefit and a consistent safety profile with up to 4.5 years of continuous treatment, according to Switzerland-based Novartis Pharma.

More... »

Foundation Medicine to provide Novartis with genetic info for oncology programs

Friday, June 8, 2012 01:00 PM

Molecular information company Foundation Medicine has extended its pilot program with Novartis to provide comprehensive genomic analysis in support of Novartis' clinical oncology programs.

More... »

Creabilis appoints Simon Russell as chief business officer

Friday, May 4, 2012 04:43 PM

Creabilis, a European biotech specializing in the development of treatments for dermatology, inflammation and pain, has appointed Simon Russell as chief business officer.

More... »